Pirfenidone is an anti-fibrotic and anti-inflammatory compound that is used to treat pulmonary fibrosis. Pirfenidone decreases fibroblast production, suppresses expression of TNF-α and IL-1β, and inhibits TGF-β-induced stimulation of collagen production. In vivo, this compound prevents the development of pulmonary fibrosis.
| Cas No. | 53179-13-8 |
|---|---|
| Purity | ≥98% |
| Formula | C12H11NO |
| Formula Wt. | 185.22 |
| IUPAC Name | 5-Methyl-1-phenyl-2(1H)-pyridinone |
| Solubility | H2O: >10 mg/mL at 60 °C (warming for 30 minutes) DMSO: >20 mg/mL |
| Appearance | Pale yellow to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Xiang XH, Jiang TP, Zhang S, et al. Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein 47 and collagen type I in rat hepatic stellate cells in vitro. Mol Med Rep. 2015 Mar 3. [Epub ahead of print]. PMID: 25738437.
Cottin V, Maher T. Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respir Rev. 2015 Mar;24(135):58-64. PMID: 25726556.
Iyer SN, Wild JS, Schiedt MJ, et al. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med. 1995 Jun;125(6):779-85. PMID: 7539478.
